NLS Pharmaceutics AG

NLSP · NASDAQ

$3.15 -4.83% (-$0.16)

Piotroski F-Score Weak

2/9

Valuation

N/A

P/E N/A

PEG N/A

EV/EBITDA N/A

Growth

N/A

EPS growth N/A

Book val. growth N/A

Rev. growth N/A

Profitability

N/A

Gross margin N/A

FCF margin N/A

Net margin N/A

Quality

N/A

ROIC N/A

Asset turnover N/A

ROE N/A

Debt

N/A

Debt/Equity N/A

Net debt/EBITDA N/A

Current ratio N/A

Stability

0 /100

Unstable

Beta 0.13x

Rev. volatility N/A

Profitable years N/A

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NLSP

Online

About the company

NLS Pharmaceutics AG (NLS) is a Swiss biotechnology company focused on the development of innovative drugs for the treatment of neurological and psychiatric disorders. With a primary focus on researching and developing medications for epilepsy and mood disorders, NLS Pharmaceutics aims to address unmet needs in the treatment of these diseases. The company is known for its expertise in pharmacology and neuroscience and for its commitment to innovation and discovering new therapeutic approaches. Shares of NLS Pharmaceutics AG (NLS) could be suitable for investors looking to invest in the biotechnology sector with an emphasis on treating neurological and psychiatric disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

Alexander Zwyer

Employees

Headquarters

Zurich

⌘ K

StockBot Live

Market situation Wall Street

Wall Street edges higher as oil and yields retreat

S&P 500 +0.08% and Nasdaq +0.30% rise as sliding oil eases Treasury yields. Europe's DAX -0.21% slips on rates.

Ask about this

StockBot knows 80,000+ stocks worldwide